NFE2L2 and neoplasm: Taken together, these results support a model in which the treatment of immune effector cells with NRF2 activators will augment their anti-cancer functionality by alleviating the tumour microenvironment-induced oxidative stress which plays a significant role in repressing anti-cancer immunity.